Influence of Vasopressors on Anti-Xa Activity in Critically Ill Patients

Medical University of Gdansk50 enrolled

Overview

Critically ill patients require antithrombotic prophylaxis. At the same time, majority of them is receiving various vasopressors. The aim of the study is to determine whether there is a difference in anti-Xa activity, which is a marker of anti thrombotic activity of low molecular weight heparins, between the patients receiving norepinephrine with argipressin, compared to those receiving norepinephrine alone.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Critical Illness Thrombosis

Interventions

Serum anti-Xa activityDIAGNOSTIC_TEST

4 hours after third dose of dalteparin, serum anti-Xa activity is measured

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Circulatory failure * Supported by continuous infusion of noradrenaline or noradrenaline and argipressin * Receiving subcutaneous dalteparin for the prevention of venous thromboembolism. Exclusion Criteria: * Contraindications for dalteparin * Severe coagulopathy * Acute or subacute bacterial endocarditis * Pregnant women * BMI (body mass index) \> 30kg/m2 * Chronic kidney disease with eGFR (estimated glomerular filtration rate) \< 30 ml/min/1.73 m2 * Renal replacement therapy * The patient died within 52 hours of starting VTE (venous thromboembolism) prophylaxis with dalteparin

Locations (1)

Medical University of Gdańsk - Departament of Anesthesiology and Intensive Care

Gdansk, Poland

RECRUITING

Outcomes

Primary Outcomes

Anti-Xa activity

IU anty-Xa/ml

Time frame: 4 hours after third dose

Central Contacts

Jan Stefaniak, MD.

CONTACT

505694054 jan.stefaniak@gumed.edu.pl

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.